Clinical trial · Interventional
Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer
Effects on QOL When Zinc is Supplemented in Patients With Upper GI Cancer on Chemotherapy
NCT03819088CI-TRIAL-00096462completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized study examines how well zinc works in improving quality of life in patients with gastrointestinal cancer that cannot be removed by surgery who are receiving chemotherapy. Zinc may help to improve patient's quality of life by preventing zinc deficiency.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Carcinoma | Gastric Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver and Intrahepatic Bile Duct Carcinoma | Liver Carcinoma | ALIAS | 0.90 |
| Unresectable Esophageal Carcinoma | Esophageal Carcinoma | CURATED_BROADER | 0.78 |
| Unresectable Pancreatic Carcinoma | Pancreatic Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Zinc | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group I (zinc months 1 and 2)
- description
- Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.
- interventionNames
- Dietary Supplement: Zinc
- type
- EXPERIMENTAL
- label
- Group II (zinc months 3 and 4)
- description
- Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.
- interventionNames
- Dietary Supplement: Zinc
Primary outcomes (1)
- measure
- Quality of life scores
- timeFrame
- Up to 4 months after study start
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients who present to adult medical oncology outpatient clinic with new diagnosis of non-resectable gastric, gastro-esophageal, pancreas or biliary cancer * Patients plan to receive chemotherapy at an Emory Cancer Center * No prior chemotherapy or radiation therapy for newly diagnosed gastric, gastro-esophageal, pancreas or biliary cancer * Patients must sign informed consent Exclusion Criteria: * Zinc supplementation is not indicated for pregnant or lactating women therefore, this is an exclusion criteria and women of childbearing age will complete a pregnancy test
References
Publications (0)
Data not yet available
No reference posted for this study.